Search results
Results from the WOW.Com Content Network
As an example, the incidence of congestive heart failure is 4.7%, 26% and 48% respectively when patients received doxorubicin at 400 mg/m 2, 550 mg/m 2 and 700 mg/m 2. [4] Therefore, the lifetime cumulative doxorubicin exposure is limited to 400–450 mg/m 2 in order to reduce congestive heart failure incidence to less than 5%, although ...
The most dangerous side effect of doxorubicin is dilated cardiomyopathy, leading to congestive heart failure. The rate of cardiomyopathy is dependent on its cumulative dose, with an incidence about 4% when the dose of doxorubicin is 500–550 mg/m 2, 18% when the dose is 551–600 mg/m 2 and 36% when the dose exceeds 600 mg/m 2. [19]
Other severe side effects include heart disease and tissue death at the site of injection. [2] Use in pregnancy may harm the fetus. [2] Daunorubicin is in the anthracycline family of medication. [3] It works in part by blocking the function of topoisomerase II. [2] Daunorubicin was approved for medical use in the United States in 1979. [2]
Idarubicin / ˌ aɪ d ə ˈ r uː b ɪ s ɪ n / or 4-demethoxydaunorubicin is an anthracycline antileukemic drug. It inserts [1] itself into DNA and prevents DNA unwinding by interfering with the enzyme topoisomerase II. It is an analog of daunorubicin, but the absence of a methoxy group increases its fat solubility and cellular uptake. [2]
The United States Food and Drug Administration has also approved a dexrazoxane for use as a treatment of extravasation resulting from IV anthracycline chemotherapy. [ 11 ] [ 12 ] Extravasation is an adverse event in which chemotherapies containing anthracylines leak out of the blood vessel and necrotize the surrounding tissue.
Two separate patients who were prescribed a popular class of antibiotic told WFTS the drug came with severe side effects. For both women, the family of antibiotics known as fluoroquinolones ...
The term 'hyper' refers to the hyperfractionated nature of the chemotherapy, which is given in smaller doses, more frequently, to minimize side effects. 'CVAD' is the acronym of the drugs used in course A: cyclophosphamide, vincristine, doxorubicin (also known by its trade name, Adriamycin), and dexamethasone.
Side effects of ABVD can be divided into acute (those occurring while receiving chemotherapy) and delayed (those occurring months to years after completion of chemotherapy). Delayed side effects have assumed particular importance because many patients treated for Hodgkin lymphoma are cured and can expect long lives after completion of chemotherapy.